8-K Announcements
6Material company update
May 6, 2026·SEC
Material company update
Mar 2, 2026·SEC
Material company update
Mar 2, 2026·SEC
UroGen Pharma Ltd.(URGN)Earnings, Financials & Key Ratios
URGN•NASDAQ
$26.25
$1.28B mkt cap·Price updated May 6, 2026
AboutUroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.Show more
- Revenue$110M+21.4%
- EBITDA-$122M-27.0%
- Net Income-$153M-21.0%
- EPS (Diluted)-3.19-7.8%
- Gross Margin88.66%-1.7%
- EBITDA Margin-111.54%-4.5%
- Operating Margin-113.73%-6.2%
- Net Margin-139.81%+0.4%
- Interest Coverage-4.08+46.6%
URGN Key Insights
UroGen Pharma Ltd. (URGN) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y sales CAGR of 56.2%
✗Weaknesses
- ✗Weak Piotroski F-Score: 1/9
- ✗Negative free cash flow
- ✗Shares diluted 12.2% in last year
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
URGN Price & Volume
UroGen Pharma Ltd. (URGN) stock price & volume — 10-year historical chart
Loading chart...
URGN Growth Metrics
UroGen Pharma Ltd. (URGN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years56.22%
3 Years19.49%
TTM52.92%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM3.76%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM13.52%
Return on Capital
10 Years-64.07%
5 Years-66.59%
3 Years-54.7%
Last Year-63.41%
URGN Recent Earnings
UroGen Pharma Ltd. (URGN) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 4/12 qtrs (33%)
Q2 2026Latest
May 6, 2026EPS
$0.47
Est $0.48
+2.6%
Revenue
$51M
Est $45M
+13.7%
Q2 2026
Mar 2, 2026EPS
$0.54
Est $0.52
-4.2%
Revenue
$38M
Est $40M
-5.2%
Q4 2025
Nov 6, 2025EPS
$0.69
Est $0.72
+4.2%
Revenue
$27M
Est $40M
-31.5%
Q3 2025
Aug 7, 2025EPS
$1.05
Est $0.82
-28.0%
Revenue
$24M
Est $34M
-27.9%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 6, 2026 | $0.47vs $0.48+2.6% | $51Mvs $45M+13.7% |
| Q2 2026 | Mar 2, 2026 | $0.54vs $0.52-4.2% | $38Mvs $40M-5.2% |
| Q4 2025 | Nov 6, 2025 | $0.69vs $0.72+4.2% | $27Mvs $40M-31.5% |
| Q3 2025 | Aug 7, 2025 | $1.05vs $0.82-28.0% | $24Mvs $34M-27.9% |
Based on last 12 quarters of dataView full earnings history →
URGN Peer Comparison
UroGen Pharma Ltd. (URGN) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 PCVX | 8.24B | 57.10 | -10.14 | -32.51% | 0.09 | |||
 SUPN | 2.96B | 51.45 | -75.66 | 8.63% | -3.74% | -2.73% | 0.04 | |
 PRGO | 1.69B | 12.26 | -1.19 | -2.75% | -43.5% | -50.65% | 1.35 | |
 PAHC | 2.38B | 58.64 | 49.28 | 27.37% | 6.29% | 30.81% | 2.67 | |
 NUVL | 6.92B | 104.26 | -26.53 | -45.12% | ||||
 TGTX | 6.7B | 41.97 | 15.15 | 87.32% | 65.95% | 87.36% | 0.40 | |
 ANIP | 1.78B | 84.06 | 25.32 | 43.78% | 8.87% | 14.49% | 0.60 | |
 CRVS | 1.15B | 15.45 | -29.15 | -23.29% | 0.02 |
Compare URGN vs Peers
UroGen Pharma Ltd. (URGN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
URGN Income Statement
UroGen Pharma Ltd. (URGN) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 8.16M | 1.13M | 18K | 11.8M | 48.04M | 64.36M | 82.71M | 90.4M | 109.79M | 140.49M |
| Revenue Growth % | -53.46% | -86.17% | -98.4% | 65450% | 307.17% | 33.96% | 28.52% | 9.29% | 21.45% | 52.92% |
| Cost of Goods Sold | 600K | 1.8M | 0 | 1.01M | 5.16M | 7.65M | 9.36M | 8.88M | 12.45M | 14.26M |
| COGS % of Revenue | 7.35% | 159.84% | - | 8.55% | 10.73% | 11.89% | 11.32% | 9.82% | 11.34% | - |
| Gross Profit | 7.56M▲ 0% | -675K▼ 108.9% | 18K▲ 102.7% | 10.79M▲ 59844.4% | 42.88M▲ 297.5% | 56.7M▲ 32.2% | 73.35M▲ 29.4% | 81.52M▲ 11.1% | 97.34M▲ 19.4% | 126.24M▲ 0% |
| Gross Margin % | 92.65% | -59.84% | 100% | 91.45% | 89.27% | 88.11% | 88.68% | 90.18% | 88.66% | 89.85% |
| Gross Profit Growth % | -56.82% | -108.93% | 102.67% | 59844.44% | 297.45% | 32.22% | 29.36% | 11.13% | 19.41% | - |
| Operating Expenses | 27.51M | 76.5M | 109.5M | 137.53M | 135.18M | 135.74M | 138.89M | 178.3M | 222.2M | 234.45M |
| OpEx % of Revenue | 337.19% | 6782.36% | 608311.11% | 1165.6% | 281.37% | 210.92% | 167.92% | 197.24% | 202.39% | - |
| Selling, General & Admin | 8.81M | 39.57M | 60.2M | 90.22M | 0 | 82.84M | 93.27M | 0 | 155.1M | 171.62M |
| SG&A % of Revenue | 108% | 3508.07% | 334438.89% | 764.63% | - | 128.72% | 112.77% | - | 141.27% | - |
| Research & Development | 18.7M | 36.93M | 49.3M | 47.31M | 47.64M | 52.91M | 45.61M | 57.15M | 67.11M | 62.83M |
| R&D % of Revenue | 229.19% | 3274.29% | 273872.22% | 400.97% | 99.17% | 82.21% | 55.15% | 63.21% | 61.12% | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 87.53M | 0 | 0 | 121.15M | 0 | 0 |
| Operating Income | -19.95M▲ 0% | -77.18M▼ 286.9% | -109.48M▼ 41.8% | -126.74M▼ 15.8% | -92.29M▲ 27.2% | -79.04M▲ 14.4% | -65.54M▲ 17.1% | -96.78M▼ 47.7% | -124.86M▼ 29.0% | -108.21M▲ 0% |
| Operating Margin % | -244.55% | -6842.2% | -608211.11% | -1074.15% | -192.11% | -122.82% | -79.23% | -107.06% | -113.73% | -77.02% |
| Operating Income Growth % | -2600% | -286.87% | -41.85% | -15.77% | 27.18% | 14.36% | 17.09% | -47.68% | -29.01% | - |
| EBITDA | -19.74M | -76.76M | -108.15M | -124.69M | -91.46M | -77.22M | -63.83M | -96.45M | -122.45M | -106.3M |
| EBITDA Margin % | -242.01% | -6805.23% | -600855.56% | -1056.83% | -190.38% | -119.99% | -77.17% | -106.7% | -111.54% | -75.66% |
| EBITDA Growth % | -2052.82% | -288.81% | -40.89% | -15.29% | 26.65% | 15.57% | 17.34% | -51.11% | -26.96% | 0.53% |
| D&A (Non-Cash Add-back) | 207K | 417K | 1.32M | 2.04M | 831K | 1.82M | 1.71M | 329K | 2.41M | 1.91M |
| EBIT | -19.95M | -77.18M | -109.48M | -124.75M | -92.29M | -78.03M | -62.06M | -95.68M | -138.07M | -98.69M |
| Net Interest Income | 125K | 1.87M | 4.33M | 1.63M | 365K | -7.5M | -12.07M | -3.62M | -27.88M | -26.02M |
| Interest Income | 125K | 1.87M | 4.62M | 1.99M | 365K | 938K | 2.64M | 8.9M | 5.96M | 3.76M |
| Interest Expense | 0 | 0 | 284K | 357K | 0 | 8.44M | 14.71M | 12.52M | 33.85M | 25.59M |
| Other Income/Expense | -31K | 1.65M | 4.33M | 1.63M | -17.08M | -28.99M | -32.79M | -27.26M | -28.55M | -30.1M |
| Pretax Income | -19.98M▲ 0% | -75.53M▼ 278.0% | -105.15M▼ 39.2% | -125.11M▼ 19.0% | -109.37M▲ 12.6% | -108.03M▲ 1.2% | -98.32M▲ 9.0% | -124.04M▼ 26.2% | -153.42M▼ 23.7% | -138.31M▲ 0% |
| Pretax Margin % | -244.93% | -6696.1% | -584144.44% | -1060.34% | -227.66% | -167.86% | -118.87% | -137.22% | -139.74% | -98.45% |
| Income Tax | 19K | 125K | 0 | 3.37M | 1.45M | 1.75M | 3.92M | 2.83M | 78K | 4.46M |
| Effective Tax Rate % | -0.1% | -0.17% | 0% | -2.7% | -1.32% | -1.62% | -3.99% | -2.28% | -0.05% | -3.22% |
| Net Income | -20M▲ 0% | -75.66M▼ 278.3% | -105.15M▼ 39.0% | -128.48M▼ 22.2% | -110.82M▲ 13.7% | -109.78M▲ 0.9% | -102.24M▲ 6.9% | -126.87M▼ 24.1% | -153.49M▼ 21.0% | -133.22M▲ 0% |
| Net Margin % | -245.16% | -6707.18% | -584144.44% | -1088.94% | -230.67% | -170.58% | -123.61% | -140.35% | -139.81% | -94.83% |
| Net Income Growth % | -930.4% | -278.28% | -38.98% | -22.2% | 13.75% | 0.94% | 6.87% | -24.09% | -20.98% | 3.76% |
| Net Income (Continuing) | -20M | -75.66M | -105.15M | -128.48M | -110.82M | -109.78M | -102.24M | -126.87M | -153.49M | -133.22M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -2.06▲ 0% | -4.80▼ 133.0% | -4.90▼ 2.1% | -5.90▼ 20.4% | -4.96▲ 15.9% | -4.79▲ 3.4% | -3.55▲ 25.9% | -2.96▲ 16.6% | -3.19▼ 7.8% | -2.65▲ 0% |
| EPS Growth % | -1187.5% | -133.01% | -2.08% | -20.41% | 15.93% | 3.43% | 25.89% | 16.62% | -7.77% | 13.52% |
| EPS (Basic) | -2.06 | -4.80 | -4.90 | -5.90 | -4.96 | -4.79 | -3.55 | -2.96 | -3.19 | - |
| Diluted Shares Outstanding | 9.72M | 15.75M | 20.53M | 21.78M | 22.35M | 22.81M | 28.83M | 42.88M | 48.12M | 50.18M |
| Basic Shares Outstanding | 9.72M | 15.75M | 20.53M | 21.78M | 22.35M | 22.81M | 28.83M | 42.88M | 48.12M | 50.18M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
URGN Balance Sheet
UroGen Pharma Ltd. (URGN) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 74.47M | 102.24M | 148.63M | 115.62M | 114.39M | 128.91M | 169.19M | 276.13M | 186.02M | 140.27M |
| Cash & Short-Term Investments | 73M | 101.32M | 147.08M | 102.02M | 89.14M | 99.96M | 136.97M | 236.69M | 120.46M | 140.27M |
| Cash Only | 37M | 101.32M | 49.69M | 52.86M | 44.36M | 55.41M | 95M | 171.99M | 110.75M | 109.97M |
| Short-Term Investments | 36M | 0 | 97.39M | 49.15M | 44.78M | 44.56M | 41.97M | 64.7M | 9.71M | 30.31M |
| Accounts Receivable | 0 | 0 | 0 | 7.05M | 11.72M | 12.7M | 15.44M | 20.3M | 33.08M | 0 |
| Days Sales Outstanding | - | - | - | 218 | 89.02 | 72.05 | 68.15 | 81.97 | 109.98 | 47.05 |
| Inventory | 316K | 0 | 0 | 1.96M | 4.83M | 4.33M | 5.67M | 9.23M | 16.46M | 0 |
| Days Inventory Outstanding | 192.23 | - | - | 710.47 | 342 | 206.25 | 221.2 | 379.22 | 482.8 | 204.4 |
| Other Current Assets | 198K | 253K | 523K | 1.23M | 1.23M | 11.91M | 11.1M | 9.92M | 16.02M | 0 |
| Total Non-Current Assets | 1.08M | 1.32M | 53.75M | 6.39M | 5.36M | 6.71M | 9.13M | 9.58M | 14.43M | 16.23M |
| Property, Plant & Equipment | 805K | 948K | 4.71M | 4.2M | 3.15M | 3.75M | 2.36M | 3.79M | 9.09M | 0 |
| Fixed Asset Turnover | 10.13x | 1.19x | 0.00x | 2.81x | 15.27x | 17.17x | 35.05x | 23.86x | 12.07x | 22.92x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 29K | 51K | 48.55M | 1.89M | 675K | 0 | 4.5M | 5.02M | 0 | 5.19M |
| Other Non-Current Assets | 244K | 317K | 487K | 289K | 1.53M | 2.96M | 2.26M | 765K | 5.34M | 29.3M |
| Total Assets | 75.55M▲ 0% | 103.56M▲ 37.1% | 202.39M▲ 95.4% | 122M▼ 39.7% | 119.75M▼ 1.9% | 135.62M▲ 13.3% | 178.31M▲ 31.5% | 285.71M▲ 60.2% | 200.46M▼ 29.8% | 253.69M▲ 0% |
| Asset Turnover | 0.11x | 0.01x | 0.00x | 0.10x | 0.40x | 0.47x | 0.46x | 0.32x | 0.55x | 0.66x |
| Asset Growth % | 227.68% | 37.07% | 95.43% | -39.72% | -1.85% | 13.26% | 31.48% | 60.23% | -29.84% | -92.05% |
| Total Current Liabilities | 7.04M | 13.46M | 19.48M | 21.44M | 22.38M | 23.92M | 31.21M | 45.95M | 46.42M | 50.63M |
| Accounts Payable | 2.84M | 4.27M | 4.69M | 3.27M | 5.79M | 5.53M | 6.51M | 10.93M | 12.14M | 0 |
| Days Payables Outstanding | 1.73K | 864.83 | - | 1.18K | 409.52 | 263.57 | 253.99 | 449.25 | 355.91 | 230.3 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 650K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | -1.6M | 0 | 1.58M | 11.41M | 10.28M | 11.53M | 14.67M | 18.52M | 34.28M | 50.63M |
| Current Ratio | 10.59x | 7.59x | 7.63x | 5.39x | 5.11x | 5.39x | 5.42x | 6.01x | 4.01x | 4.01x |
| Quick Ratio | 10.54x | 7.59x | 7.63x | 5.30x | 4.90x | 5.21x | 5.24x | 5.81x | 3.65x | 3.65x |
| Cash Conversion Cycle | - | - | - | -254.8 | 21.5 | 14.73 | 35.36 | 11.94 | 236.87 | 21.14 |
| Total Non-Current Liabilities | 0 | 0 | 2.6M | 4.21M | 88.95M | 201.06M | 212.31M | 248.56M | 259.51M | 327.31M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 97.54M | 98.55M | 121.73M | 122.21M | 195.18M |
| Capital Lease Obligations | 0 | 0 | 2.6M | 1.5M | 398K | 1.59M | 844K | 1.65M | 6.12M | 15.78M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 2.72M | 2.84M | 3.02M | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 85.71M | 98.92M | 112.92M | 125.18M | 131.18M | 521.79M |
| Total Liabilities | 7.04M | 13.46M | 22.09M | 25.65M | 111.33M | 224.98M | 243.52M | 294.51M | 305.93M | 377.94M |
| Total Debt | 0 | 0 | 2.6M | 1.5M | 398K | 99.12M | 99.39M | 123.39M | 128.33M | 195.18M |
| Net Debt | -37M | -101.32M | -47.08M | -51.37M | -43.96M | 43.72M | 4.39M | -48.6M | 17.59M | 85.21M |
| Debt / Equity | - | - | 0.01x | 0.02x | 0.05x | - | - | - | - | -1.57x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -1.84x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.80x |
| Interest Coverage | - | - | -385.49x | -349.45x | - | -9.25x | -4.22x | -7.64x | -4.08x | -3.86x |
| Total Equity | 68.52M▲ 0% | 90.09M▲ 31.5% | 180.3M▲ 100.1% | 96.36M▼ 46.6% | 8.41M▼ 91.3% | -89.36M▼ 1162.2% | -65.21M▲ 27.0% | -8.8M▲ 86.5% | -105.47M▼ 1098.2% | -124.25M▲ 0% |
| Equity Growth % | 320.16% | 31.5% | 100.13% | -46.56% | -91.27% | -1162.18% | 27.02% | 86.5% | -1098.16% | -2225.96% |
| Book Value per Share | 7.05 | 5.72 | 8.78 | 4.42 | 0.38 | -3.92 | -2.26 | -0.21 | -2.19 | -2.48 |
| Total Shareholders' Equity | 68.52M | 90.09M | 180.3M | 96.36M | 8.41M | -89.36M | -65.21M | -8.8M | -105.47M | -124.25M |
| Common Stock | 37K | 44K | 57K | 60K | 61K | 63K | 89K | 115K | 133K | 134K |
| Retained Earnings | -47.21M | -122.87M | -228.02M | -356.5M | -467.32M | -577.1M | -679.35M | -806.22M | -959.72M | -983.29M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -577K | -747K | 276K | 271K | -25K | -107K | 12K | 56K | 19K | 8K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
URGN Cash Flow Statement
UroGen Pharma Ltd. (URGN) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -9.57M | -37.33M | -71.02M | -105.89M | -84.89M | -87.56M | -76.38M | -96.77M | -162.44M | -162.44M |
| Operating CF Margin % | -117.32% | -3309.75% | -394538.89% | -897.41% | -176.7% | -136.05% | -92.34% | -107.04% | -147.96% | - |
| Operating CF Growth % | -328.48% | -290.07% | -90.22% | -49.1% | 19.83% | -3.14% | 12.77% | -26.7% | -67.87% | -309.74% |
| Net Income | -20M | -75.66M | -105.15M | -128.48M | -110.82M | -109.78M | -102.24M | -126.87M | -153.49M | -133.22M |
| Depreciation & Amortization | 207K | 417K | 1.32M | 2.04M | 1.77M | 1.82M | 1.71M | 1.19M | 2.41M | 2.57M |
| Stock-Based Compensation | 6.3M | 30.64M | 29.97M | 28.02M | 23.11M | 10.58M | 9.34M | 13.11M | 11.96M | 13.52M |
| Deferred Taxes | 0 | 0 | -572K | 439K | 15.32M | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 165K | 100K | -910K | -1.54M | -1.18M | 16.13M | 11.48M | 10.88M | 4.59M | -25.48M |
| Working Capital Changes | 3.76M | 7.16M | 4.32M | -6.37M | -13.11M | -6.31M | 3.34M | 4.93M | -27.91M | -23.11M |
| Change in Receivables | 83K | 3.29M | 0 | -7.05M | -4.67M | -987K | -2.74M | -4.86M | -12.78M | -36.58M |
| Change in Inventory | -211K | 316K | 0 | -1.96M | -2.87M | -362K | -1.35M | -3.55M | -7.24M | -13.81M |
| Change in Payables | 2.53M | 4.21M | 2.93M | -1.25M | 2M | 281K | 4.16M | 10.89M | 286K | 9.25M |
| Cash from Investing | -36.38M | 35.29M | -145.59M | 93.24M | 4.07M | 1.06M | -953K | -20.61M | 61.56M | 66.83M |
| Capital Expenditures | -271K | -560K | -325K | -1.22M | -752K | -254K | -194K | -295K | -289K | -299K |
| CapEx % of Revenue | 3.32% | 49.65% | 1805.56% | 10.3% | 1.57% | 0.39% | 0.23% | 0.33% | 0.26% | - |
| Acquisitions | 0 | 0 | 0 | -94.45M | -4.82M | -1.31M | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -105K | -54K | -172K | 94.45M | 4.82M | 1.31M | 0 | 0 | 0 | 0 |
| Cash from Financing | 61.59M | 66.42M | 165.25M | 16.53M | 72.32M | 97.13M | 116.93M | 194.62M | 39.92M | 105.09M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 95.78M | 0 | 24.49M | -1.85M | -1.97M |
| Equity Issued (Net) | 60.84M | 64.23M | 161.66M | 15.85M | -83K | 1.35M | 67.36M | 151.17M | 41.77M | -34K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 744K | 2.19M | 3.59M | 674K | 72.4M | 0 | 49.57M | 18.96M | 0 | 107.09M |
| Net Change in Cash | 15.64M▲ 0% | 64.37M▲ 311.7% | -51.36M▼ 179.8% | 3.88M▲ 107.6% | -8.5M▼ 319.2% | 10.63M▲ 225.1% | 39.6M▲ 272.4% | 77.24M▲ 95.0% | -60.97M▼ 178.9% | 6.19M▲ 0% |
| Free Cash Flow | -9.84M▲ 0% | -37.89M▼ 285.0% | -71.34M▼ 88.3% | -107.1M▼ 50.1% | -85.64M▲ 20.0% | -87.81M▼ 2.5% | -76.57M▲ 12.8% | -97.06M▼ 26.8% | -162.73M▼ 67.7% | -166.03M▲ 0% |
| FCF Margin % | -120.64% | -3359.4% | -396344.44% | -907.71% | -178.27% | -136.45% | -92.57% | -107.37% | -148.22% | -118.18% |
| FCF Growth % | -381.68% | -285.02% | -88.27% | -50.12% | 20.03% | -2.53% | 12.8% | -26.76% | -67.66% | -54.6% |
| FCF per Share | -1.01 | -2.41 | -3.48 | -4.92 | -3.83 | -3.85 | -2.66 | -2.26 | -3.38 | -3.38 |
| FCF Conversion (FCF/Net Income) | 0.48x | 0.49x | 0.68x | 0.82x | 0.77x | 0.80x | 0.75x | 0.76x | 1.06x | 1.25x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
URGN Key Ratios
UroGen Pharma Ltd. (URGN) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -47.16% | -95.4% | -77.77% | -92.88% | -211.55% | - | - | - | - | 121.52% |
| Return on Invested Capital (ROIC) | -113.09% | -570.52% | -134.61% | -106.68% | -1466.66% | - | - | - | - | 124.26% |
| Gross Margin | 92.65% | -59.84% | 100% | 91.45% | 89.27% | 88.11% | 88.68% | 90.18% | 88.66% | 89.85% |
| Net Margin | -245.16% | -6707.18% | -584144.44% | -1088.94% | -230.67% | -170.58% | -123.61% | -140.35% | -139.81% | -94.83% |
| Debt / Equity | - | - | 0.01x | 0.02x | 0.05x | - | - | - | - | -1.57x |
| Interest Coverage | - | - | -385.49x | -349.45x | - | -9.25x | -4.22x | -7.64x | -4.08x | -3.86x |
| FCF Conversion | 0.48x | 0.49x | 0.68x | 0.82x | 0.77x | 0.80x | 0.75x | 0.76x | 1.06x | 1.25x |
| Revenue Growth | -53.46% | -86.17% | -98.4% | 65450% | 307.17% | 33.96% | 28.52% | 9.29% | 21.45% | 52.92% |
URGN SEC Filings & Documents
UroGen Pharma Ltd. (URGN) SEC filings — annual & quarterly reports (10-K, 10-Q)
URGN Frequently Asked Questions
UroGen Pharma Ltd. (URGN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
UroGen Pharma Ltd. (URGN) reported $140.5M in revenue for fiscal year 2025.
UroGen Pharma Ltd. (URGN) grew revenue by 21.4% over the past year. This is strong growth.
UroGen Pharma Ltd. (URGN) reported a net loss of $133.2M for fiscal year 2025.
Dividend & Returns
UroGen Pharma Ltd. (URGN) had negative free cash flow of $166.0M in fiscal year 2025, likely due to heavy capital investments.
Explore More URGN
UroGen Pharma Ltd. (URGN) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates